Summary: A new study based on data from 18,740 dementia patients suggests that antidepressants can accelerate cognitive decline. Researchers found that patients taking antidepressants, especially SSRIs such as escatalopram, seatalopram, and serrtrane, experience a rapid decline compared to those compared to the drug.
While depression can only spoil the symptoms of dementia, findings highlight the requirement of more sewn antidepressant options in dementia care. Future research will find out whether patients affect specific dementia types or biomarkers how patients react to different antidepressants.
Important facts
- Rapid cognitive decline: Patients from dementia on antidepressants showed more cognitive decline over time.
- SSRI Effect: Escitalopram, Citalopram, and Sertraline were associated with the fastest decline, while Mirtazapine had a major impact.
- Personal care required: Researchers aim to identify patient subgrhis who can give better or worse response to specific antidepressants.
Source: Karolinska institute
New research suggests that antidepressants can accelerate cognitive decline in people with dementia. At the same time, some medicines appear to be less harmful than others, which can help doctors to make better treatment decisions, according to the published study. BMC Medicine.
Antidepressants are often used to relieve symptoms such as anxiety, depression, aggression and sleep disturbances in dementia victims.
However, a new observation study based on the data of the Swedish Dementia Registry (SVEDEM) suggests that patients with dementia are treated with antidepressants, who do not receive this medicine compared to an increased cognitive Experience the fall.
The study is based on a comprehensive analysis of registry data of 18,740 patients, about 23 percent of which was treated with antidepressants. During the study, a total of 11,912 tips of the antidepressant were registered, with selective serotonin Reppete inhibitor (SSRI) accounting for 65 percent.
“Symptoms of depression can spoil both cognitive decline and the quality of life, so it is important to treat them. Our results can help doctors and other healthcare professionals to choose antidepressants who are better adapted to patients with dementia, ”Sarah Garcia Passak, Neurobiology, Care Sciences and Society, Karolinska Institute and Final Writer’s final writer researcher Sarah Garcia Pesak says.
Researchers at the Karolinska Institute and Sahalinkka University Hospital in Gothenburg have followed the cognitive development of patients over time and compared both medicated and non-medicated groups as well as a variety of antidepressants.
Although it is not possible to determine whether cognitive harm is due to drugs or due to symptoms of depression, researchers were able to see that antidepressants were associated with increased cognitive decline.
Difference between drugs
The study also indicates the difference between various drugs. The SSRI Escitalopram was associated with the fastest cognitive decline, followed by SSRIS Citalopram and Servarline.
Mirtazapine, which has a separate mechanism of action, had less negative cognitive effects than Escitalopram.
Researchers now want to check whether some patient groups, such as people with specific dementia types or biomarckers, respond better or worse to separate antidepressants.
“The goal is to find these subgroups to create more personal care,” Sara Garcia says PTACEK.
Funding: The study has been funded by a personal initiative from Swedish Research Council, Region Stockholm, Swedish Dementia Research Foundation, Alzheimer’s Foundation and New Innovative Rods Calls – Leaf Lundblad family and others. Researchers did not report a conflict of interest.
About this psychopharmacology and cognition research news
Author: Press Office
Source: Karolinska institute
contact: Press Office – Karolinska Institute
image: The image is credited to Neuroscience News
Basic Research: Conclusions will be seen BMC Medicine
